Hold XOM core position at $166; scale in on staged pullbacks to $161/$157/$147.80 with hard stop at $147.80
HOLD rating is compelled by three sequential Underweight failures (8/13, 8/14, 8/17) that collectively cost +5.6% alpha as the structural floor (0.47x net leverage, 40+ year dividend growth, $37.5B capital return program, rising 200 SMA) consistently absorbed selling pressure. The current setup at $166 with RSI 71.79 is materially more extreme than the failed August 2026-08-17 call (RSI 66.27 then). Patience is the alpha source—do not chase at elevated RSI; await staged entry at $161/$157/$147.80 or Q3 earnings catalyst.
| Position | Action |
|---|---|
| RSI 60-65 with 10 EMA touch at $161 | Deploy 33% of target tranche |
| 20 SMA touch at $157 | Deploy 33% of target tranche |
| 50 SMA touch at $147.80 | Deploy final 34% of target tranche |
| Weekly close below $147.80 | Hard stop on any new tranche; exit scaled positions |
| Weekly close below $140 (200 SMA) | Trigger Underweight reassessment |
XOM is in an earnings inflection point with fortress financials and structural macro tailwinds, making any pullback a buying opportunity.
| Indicator | Value | Signal |
|---|---|---|
| Close | 166.15 | neutral |
| 50 SMA | 147.80 | bullish |
| 200 SMA | 140.47 | bullish |
| 10 EMA | 161.03 | bullish |
| RSI (14) | 71.79 | neutral |
| MACD | 4.46 | bullish |
| MACD Histogram | 0.76 | bullish |
| Bollinger Upper Band | 166.24 | neutral |
| ATR (14) | 3.66 | neutral |
Support: 161.03 · 157.12 · 147.8 · 140.47 | Resistance: 166.24 · 165.67
XOM is in a decisive multi-month uptrend with price 18.3% above the 200 SMA and 12.4% above the 50 SMA, both moving averages rising and widening apart—a classic late-stage bullish expansion. The stock is extended at 166.15, touching the upper Bollinger Band with RSI at 71.79, though prior RSI readings at 72.35 and 72.17 saw only small pullbacks before resuming. MACD at 4.46 with expanding histogram at 0.76 confirms fresh acceleration phase with no bearish divergence yet. Key support levels are 161.03 (10 EMA), 157.12 (20 SMA), 147.80 (50 SMA), and 140.47 (200 SMA); immediate resistance sits at 166.24. Trading recommendation: HOLD existing longs with trailing stops, WAIT for pullbacks to 161–157 for new entries, and watch for bearish RSI divergence as the first exhaustion warning.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price at $157 (20 SMA), intact trend structure, 33% tranche
Then: Buy 33% of target position
↩ rebuts: “Bear claims of high capex creeping up creating leverage risk”
· concedes: RSI is at 71.79, price pinned to upper Bollinger Band at 166.24, stock ~12% above 50 SMA and ~18% above 200 SMA (but reframed as healthy late-stage bullish expansion); Kazakhstan Tengiz field potentially peaking within years (but dismissed as irrelevant for 2026-2027 cash flows); CapEx rose from $18.4B (2022) to $28.4B (2025) (but defended as funding higher-return assets)
XOM at $166 is a late-cycle momentum trade with deteriorating risk/reward, fragile macro assumptions, and structural headwinds that make it a sell rather than a long-term investment.
· concedes: The trend is up and XOM has strong capital return program; Guyana volumes are rising and LNG projects have long-term potential; The dividend appears secure at current oil prices; Rising 50/200 SMAs confirm short-term momentum is positive
→ vs conservative: The RSI 71.79 and 12% premium to 50 SMA are not overbought warnings but confirmation signals in a confirmed uptrend; waiting for $148 creates opportunity cost, not discipline
→ vs conservative: The cyclical peak narrative is flawed—Q2 2026 earnings of $14.83B net income and $17.03B FCF is a base for growth, not a peak; 37% forward earnings recovery still coming
→ vs conservative: No clear catalyst exists to send XOM down 11% to $148 given zero probability Iran nuclear deal, 18% US invasion odds, and sticky geopolitical premium
→ vs neutral: The $37.5 billion annual capital return program is being treated as background noise; it creates a 5-6% return floor plus removes 2.5% of float annually through buybacks
→ vs neutral: Macro tailwinds are not fully priced in—37% forward earnings recovery at 15.5x PE is not a priced-in scenario; consensus earnings still need to catch up to commodity tape
→ vs neutral: Fair value is a misnomer in a name with this capital return velocity and geopolitical tailwind; balance sheet flex alone justifies more aggressive stance
Market Capitalization
$683.2B
PE Ratio (TTM)
21.36x
Forward PE
15.56x
PEG Ratio
1.29
Price-to-Book
2.63x
Dividend Yield
2.50%
Beta
0.173
52-Week High
$176.41
52-Week Low
$107.96
50-Day Moving Average
$148.33
200-Day Moving Average
$142.05
EPS (TTM)
$7.78
Forward EPS
$10.68
Revenue (TTM)
$361.06B
Gross Profit (TTM)
$107.48B
EBITDA (TTM)
$67.94B
Net Income (TTM)
$32.76B
Gross Margin (TTM)
~29.8%
Operating Margin
15.86%
Net Profit Margin
9.07%
ROE
12.58%
ROA
5.52%
EBITDA Margin
18.8%
Total Assets
$464.5B
Total Equity
$259.38B
Total Debt
$42.37B
Net Debt
$31.78B
Long-Term Debt
$32.2B
Short-Term Debt
$10.1B
Cash & Equivalents
$10.6B
Net PPE
$296.30B
Working Capital
$11.96B
Current Ratio
1.135
Book Value per Share
$63.08
Debt-to-Equity
0.16
Operating Cash Flow (TTM)
~$59.7B
Free Cash Flow (TTM)
$20.67B
CapEx (TTM)
~$29.2B
Dividends Paid (2025)
$17.23B
Buybacks (2025)
$20.27B
Total Capital Returns (2025)
$37.50B
Capital Returns Payout Ratio
~73%
Q2 2026 Revenue
$114.53B
Q2 2026 Gross Profit
$25.79B
Q2 2026 Operating Income
$18.20B
Q2 2026 EBITDA
$28.34B
Q2 2026 Net Income
$14.83B
Q2 2026 EPS
$3.48
Q2 2026 FCF
$17.03B
Q2 2026 OCF
$23.56B
Q2 2026 CapEx
$6.53B
2025 Revenue
$323.91B
2025 Gross Profit
$71.24B
2025 Operating Income
$33.94B
2025 Net Income
$28.84B
2025 EPS
$6.70
2025 FCF
$23.61B
2025 OCF
$51.97B
2025 CapEx
$28.36B
2024 Revenue
$339.25B
2024 Net Income
$33.68B
2024 EPS
$7.84
2023 Revenue
$334.70B
2023 Net Income
$36.01B
2023 EPS
$8.89
2022 Revenue
$398.68B
2022 Net Income
$55.74B
2022 EPS
$13.26
4-Year Capital Returns
~$136B+
Share Count Change
-4.6%
Treasury Stock (2022)
$240B
Treasury Stock (Q2 2026)
$268B
Pension Obligations (Non-Current)
$9.07B
Net Tangible Assets
$259.38B
2022 Net Debt
$8.25B
2023 Net Debt
$6.20B
2024 Net Debt
$14.73B
2025 Net Debt
$26.54B
2026 Q2 Net Debt
$31.78B
Strengths
Concerns
XOM is a mega-cap integrated energy Dividend Aristocrat trading near its 52-week high at $683B market cap, with fortress balance sheet (D/E 0.16), exceptional capital discipline (returned ~$136B+ to shareholders over 4 years), and a renewed earnings upcycle evidenced by Q2 2026's $14.83B net income and $17.03B FCF. The company shows strong profitability metrics (12.58% ROE, 9.07% net margin, 18.8% EBITDA margin) and trades at a forward PE of 15.56x with analysts projecting ~37% EPS growth ($7.78 TTM to $10.68 forward). Primary risks include commodity price cyclicality, energy transition headwinds, and the stock being extended ~12% above its 50-day moving average, supporting a HOLD stance with prudent entries on weakness toward $148-$142.
Macro: Oil prices are surging on renewed US-Iran hostility and Strait of Hormuz risk, driving Brent above $93–$95/bbl and WTI above $85, which has triggered a bond selloff, equity pullback, and repricing of inflation expectations with Polymarket now pricing 86% probability of NO Fed rate cuts in 2026. Soft-landing consensus holds with only 8% recession probability, but sticky energy-driven inflation and hawkish Fed expectations contrast with consumer weakness (Walmart miss). Geopolitical war premium is sustained by 0% odds of a US-Iran nuclear deal by August 31, 2026 and 18% odds of US invasion before 2027 ($59M in Polymarket volume).